BRIEF-GSK files regulatory submission for variation to marketing authorisation for Ambrisentan

* GSK press release: GSK announces EU regulatory submission seeking extended indication for Ambrisentan (Volibris) in pulmonary arterial hypertension
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.